Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788159 | 0.90 | NPY1R (0.52) | NPY1RABCB1GAAACP1KCNH2 | |
| SCHEMBL7791107 | 0.78 | SMPD1 (0.44) | ABCB1GAALMNAALDH1A1MAPT | |
| SCHEMBL7791844 | 0.75 | NPY1R (0.43) | NPY1RGAALMNAALDH1A1MAPT | |
| SCHEMBL7783153 | 0.75 | NPY1R (0.43) | NPY1RGAALMNAALDH1A1MAPT | |
| SCHEMBL7783150 | 0.74 | RECQL (0.38) | NPY1RABCB1GAALMNAALDH1A1 | |
| SCHEMBL9067860 | 0.71 | ALDH1A1 (0.61) | ACP1LMNAALDH1A1MAPTMEN1 | |
| SCHEMBL7676276 | 0.69 | CRHR1 (0.49) | ALDH1A1MEN1KMT2ARXFP1TP53 | |
| SCHEMBL7783147 | 0.68 | CRHR1 (0.53) | NPY1RALDH1A1TP53 | |
| SCHEMBL7791105 | 0.68 | CRHR1 (0.41) | NPY1RCD38MEN1KMT2A | |
| SCHEMBL7792988 | 0.67 | MAPT (0.48) | GAALMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
| US-6221875-B1 | TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | NPY1R 1/4885ABCB1 3180/4885GAA 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.